Spring Phcl Seminar Series - 10:00 AM
"If we knew then what we know now would we have approached the development of endocrine therapies for breast cancer differently?”
Donald McDonnell, PhD
Professor of Pharmacology and Cancer Biology
Dr. Donald McDonnell is the Glaxo-Wellcome Professor of Molecular Cancer Biology in the Department of Pharmacology and Cancer Biology at Duke University School of Medicine. His research focuses on the development and application of mechanism-based approaches to identify novel therapeutics for use in the treatment and prevention of hormonally responsive cancers. Specifically, he is engaged in the pharmaceutical exploitation of the estrogen and androgen receptors as therapeutic targets in breast and prostate cancers and in defining how these receptors influence the pathogenesis of these diseases. From these studies have emerged several drugs that are at various stages of clinical development. He received his PhD from Baylor College of Medicine, and his BSc in Biochemistry at the National University of Ireland, Galway. He is a member of the National Academy of Medicine and the National Academy of Inventors.